AccurKardia Software Platform Receives MedTech Breakthrough Award

May 8, 2025 – AccurKardia, an innovator in ECG-based diagnostics technology, recently announced that its AccurECG software platform was selected as winner of the “Best New Technology Solution for ECG” award in the 9^th annual MedTech Breakthrough Awards. The program is conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies, and products in the global digital health and medical technology market.

AccurECG⁽¹⁾ provides automated, near real-time beat-by-beat ECG analysis across multiple arrhythmias, including atrial fibrillation, atrial flutter and other critical events. Device-agnostic and vendor neutral, the platform seamlessly integrates with diverse hardware including short duration recordings from ECG systems and multi-day Holter or patch monitors. AccurECG’s flexible API allows clinical and commercial partners to be swiftly integrated into existing workflows, reducing turnaround times and enhancing cardiac technicians’ capabilities in pinpointing dangerous cardiac arrhythmias and treating patients earlier. 

Beyond AccurECG, AccurKardia is working to expand the use of ECGs as a broad biomarker. In 2024, AccurKardia received FDA Breakthrough Device Designations for two novel applications:

• AK-AVS² – An ECG-based AI algorithm that screens for and enables early detection of moderate to severe Aortic Valve Stenosis, targeting a largely underdiagnosed yet life-threatening condition.
• AK+ Guard² – A Lead I ECG-based, AI-powered hyperkalemia detection tool designed for consumer and clinical wearables, which was also accepted into the FDA’s highly selective Total Product Life Cycle (TAP) program. This tool extends hyperkalemia detection outside of the clinic and helps to identify moderate to severe episodes of hyperkalemia (excess potassium in the blood) that can lead to sudden cardiac arrest. 

“By pioneering these breakthrough ECG-based solutions, AccurKardia is redefining cardiac diagnostics — making them more accessible, actionable, and predictive, ultimately transforming how we detect, treat, and prevent life-threatening conditions,” said Steve Johansson, managing director, MedTech Breakthrough.

“We are grateful to MedTech Breakthrough for recognizing AccurECG as the ‘Best New Technology Solution for ECG,’” said Juan C. Jimenez, co-founder and CEO of AccurKardia. “We will continue to deliver innovative solutions that align with our mission to improve patient outcomes and save lives globally, transforming ECGs into a more powerful arrhythmia detection tool and broad biomarker for cardiology and beyond.”

The MedTech Breakthrough Awards program celebrates excellence and innovation in the health and medical technology industry, recognizing the companies, products and solutions driving progress and improving patient care. Spanning a wide range of categories—including Telehealth, Clinical Administration, Patient Engagement, Electronic Health Records, Virtual Care, Medical Devices, Medical Data & Privacy, and beyond — the awards highlight the  work that is transforming the healthcare landscape. 

This year’s program saw a record-breaking number of nominations from leading companies and startups across more than 18 countries, showcasing the global impact and momentum of the digital healthcare industry today.

1. For detailed technical AccurECG requirements, relevant disclosures, and approved indications for use, please refer to the U.S. FDA 510(k) K223013 summary and product labeling.
2. AK-AVS and AK+ Guard are currently for research use only and have not been cleared or approved by the U.S. FDA for use in the United States. This technology is under development and intended solely for investigational purposes.